Literature DB >> 17084910

Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls.

K F Haegele1, C A Stueckle, J-P Malin, E Sindern.   

Abstract

CCR7 and CD45RA expression on CD4+ and CD8+ T-cells in blood (PB) of 16 patients with multiple sclerosis (MS) and 16 healthy controls and cerebrospinal fluid (CSF) of 10 patients suffering from MS were analysed by flow cytometric measurements. T-cells were divided by their distinct homing potentials and effector-functions in three groups: naïve T-cells (CCR7+, CD45RA+), central memory T-cells (TCM) (CCR7+, CD45RA-) and effector memory T-cells (TEM) (CCR7-, CD45RA-). There was a significant increase of CD8+ TEM-cells in PB of MS patients compared to healthy controls, indicating systemic immune activation. Further we found a relative depletion of CD8+ TEM-cells in CSF of MS patients compared to matching blood samples, suggesting that these cells represent the effector arm of the immune response and infiltrate the brain tissue at the sites of inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17084910     DOI: 10.1016/j.jneuroim.2006.09.008

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

1.  Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Authors:  M W Pennington; C Beeton; C A Galea; B J Smith; V Chi; K P Monaghan; A Garcia; S Rangaraju; A Giuffrida; D Plank; G Crossley; D Nugent; I Khaytin; Y Lefievre; I Peshenko; C Dixon; S Chauhan; A Orzel; T Inoue; X Hu; R V Moore; R S Norton; K G Chandy
Journal:  Mol Pharmacol       Date:  2009-01-02       Impact factor: 4.436

2.  Efficiency of long-term treatment with intravenous immunoglobulins correlates with reduced autoreactive T cell responses in chronic inflammatory demyelinating polyneuropathy patients.

Authors:  J Klehmet; C Meisel; A Meisel
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 3.  Novel therapies for memory cells in autoimmune diseases.

Authors:  P Bhargava; P A Calabresi
Journal:  Clin Exp Immunol       Date:  2015-04-23       Impact factor: 4.330

Review 4.  Alternative splicing in multiple sclerosis and other autoimmune diseases.

Authors:  Irina Evsyukova; Jason A Somarelli; Simon G Gregory; Mariano A Garcia-Blanco
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 5.  Multiple sclerosis: molecular mechanisms and therapeutic opportunities.

Authors:  Djordje Miljković; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2013-04-22       Impact factor: 8.401

6.  Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.

Authors:  Melanie P Matheu; Christine Beeton; Adriana Garcia; Victor Chi; Srikant Rangaraju; Olga Safrina; Kevin Monaghan; Marc I Uemura; Dan Li; Sukumar Pal; Luis M de la Maza; Edwin Monuki; Alexander Flügel; Michael W Pennington; Ian Parker; K George Chandy; Michael D Cahalan
Journal:  Immunity       Date:  2008-10-02       Impact factor: 31.745

7.  The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blocker.

Authors:  Xiao-Fang Yang; Yong Yang; Yi-Tian Lian; Zhao-Hui Wang; Xiao-Wei Li; Long-Xian Cheng; Jin-Ping Liu; Yan-Fu Wang; Xiang Gao; Yu-Hua Liao; Min Wang; Qiu-Tang Zeng; Kun Liu
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

8.  Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis.

Authors:  Michael P Pender; Peter A Csurhes; Casey Mm Pfluger; Scott R Burrows
Journal:  Mult Scler       Date:  2014-05-19       Impact factor: 6.312

Review 9.  Splicing Regulation of Pro-Inflammatory Cytokines and Chemokines: At the Interface of the Neuroendocrine and Immune Systems.

Authors:  Felitsiya Shakola; Parul Suri; Matteo Ruggiu
Journal:  Biomolecules       Date:  2015-09-07

10.  Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations.

Authors:  James Dooley; Ine Pauwels; Dean Franckaert; Ide Smets; Josselyn E Garcia-Perez; Kelly Hilven; Dina Danso-Abeam; Joanne Terbeek; Anh T L Nguyen; Louis De Muynck; Brigitte Decallonne; Bénédicte Dubois; Adrian Liston; An Goris
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.